Show simple item record

dc.contributor.authorDakin, SGen_US
dc.contributor.authorColas, RAen_US
dc.contributor.authorNewton, Jen_US
dc.contributor.authorGwilym, Sen_US
dc.contributor.authorJones, Nen_US
dc.contributor.authorReid, HABen_US
dc.contributor.authorWood, Sen_US
dc.contributor.authorAppleton, Len_US
dc.contributor.authorWheway, Ken_US
dc.contributor.authorWatkins, Ben_US
dc.contributor.authorDalli, Jen_US
dc.contributor.authorCarr, AJen_US
dc.date.accessioned2019-07-01T09:39:38Z
dc.date.available2019-06-05en_US
dc.date.issued2019-07en_US
dc.identifier.urihttps://qmro.qmul.ac.uk/xmlui/handle/123456789/58279
dc.description.abstractResolution of inflammation is poorly understood in Achilles tendon disorders. Herein, we investigated the bioactive lipid mediator profiles of tendon-derived stromal cells isolated from patients with Achilles tendinopathy (AT) or Achilles rupture (AR) under baseline and IL-1β-stimulated conditions. We also determined whether incubating these cells with 2 of the mediators produced by tendon-derived stromal cells, 15-epi-Lipoxin A4 (15-epi-LXA4) or maresin (MaR)-1, moderated their proinflammatory phenotype. Under baseline conditions, AT cells showed concurrent increased levels of proinflammatory eicosanoids and proresolving mediators compared with AR cells. IL-1β treatment induced profound prostaglandin E2 release in AR compared with AT cells. Incubation of IL-1β treated AT and AR tendon-derived stromal cells in 15-epi-LXA4 or MaR1 reduced proinflammatory eicosanoids and potentiated the release of proresolving mediators. These mediators also induced specialized proresolving mediator (SPM) biosynthetic enzymes arachidonate lipoxygenase (ALOX) 12 and ALOX15 and up-regulated the proresolving receptor ALX compared with vehicle-treated cells. Incubation in 15-epi-LXA4 or MaR1 also moderated the proinflammatory phenotype of AT and AR cells, regulating podoplanin, CD90, signal transducer and activator of transcription (STAT)-1, IL-6, IFN regulatory factor (IRF) 5, and TLR4 and suppressed c-Jun N-terminal kinase 1/2/3, Lyn, STAT-3, and STAT-6 phosphokinase signaling. In summary, we identify proresolving mediators that are active in AT and AR and propose SPMs, including 15-epi-LXA4 or MaR1, as a potential strategy to counterregulate inflammatory processes in these cells.-Dakin, S. G., Colas, R. A., Newton, J., Gwilym, S., Jones, N., Reid, H. A. B., Wood, S., Appleton, L., Wheway, K., Watkins, B., Dalli, J., Carr, A. J. 15-Epi-LXA4 and MaR1 counter inflammation in stromal cells from patients with Achilles tendinopathy and rupture.en_US
dc.description.sponsorshipEuropean Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (Grant 677542en_US
dc.description.sponsorshipBarts Charity (Grant MGU0343)en_US
dc.description.sponsorshipSir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (Grant 107613/Z/15/Z)en_US
dc.format.extent8043 - 8054en_US
dc.languageengen_US
dc.language.isoenen_US
dc.relation.ispartofFASEB Jen_US
dc.rightsCreative Commons Attribution 4.0 International (CC BY 4.0)
dc.subject15-epi-LipoxinAen_US
dc.subjectmaresin-1en_US
dc.subjectresolutionen_US
dc.subjecttendonen_US
dc.title15-Epi-LXA4 and MaR1 counter inflammation in stromal cells from patients with Achilles tendinopathy and rupture.en_US
dc.typeArticle
dc.rights.holder© The Author(s) 2019
dc.identifier.doi10.1096/fj.201900196Ren_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/30916999en_US
pubs.issue7en_US
pubs.notesNot knownen_US
pubs.publication-statusPublisheden_US
pubs.volume33en_US
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/en_US
qmul.funderSir Henry Dale Fellowship::Wellcome Trusten_US
qmul.funderSir Henry Dale Fellowship::Wellcome Trusten_US
qmul.funderSir Henry Dale Fellowship::Wellcome Trusten_US


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record